

Research Article

Cite this article: Cardoso Santos C, Meuser Batista M, Inam Ullah A, Rama Krishna Reddy T, Soeiro MdeNC (2021). Drug screening using shape-based virtual screening and *in vitro* experimental models of cutaneous Leishmaniasis. *Parasitology* **148**, 98–104. <https://doi.org/10.1017/S0031182020001900>

Received: 2 June 2020

Revised: 29 September 2020

Accepted: 30 September 2020

First published online: 7 October 2020


Key words:

Cutaneous leishmaniasis; *in vitro* experimental chemotherapy; *Leishmania amazonensis*; shape-based virtual screening

Author for correspondence:

Maria de Nazaré Correia Soeiro,
E-mail: soeiro@ioc.fiocruz.br

Drug screening using shape-based virtual screening and *in vitro* experimental models of cutaneous Leishmaniasis

Camila Cardoso Santos¹, Marcos Meuser Batista¹, Asma Inam Ullah²,
Tummala Rama Krishna Reddy² and Maria de Nazaré Correia Soeiro¹ 

¹Laboratory of Cellular Biology (LBC), Oswaldo Cruz Institute (IOC/FIOCRUZ), CEP21040-360, Rio de Janeiro, RJ, Brazil and ²The Medicines Research Group, School of Health, Sport and Bioscience, College of Applied Health and Communities, University of East London, Stratford Campus, Water Lane, London, UK

Abstract

Cutaneous leishmaniasis (CL) is one of the most disregarded tropical neglected disease with the occurrence of self-limiting ulcers and triggering mucosal damage and stigmatizing scars, leading to huge public health problems and social negative impacts. Pentavalent antimonials are the first-line drug for CL treatment for over 70 years and present several drawbacks in terms of safety and efficacy. Thus, there is an urgent need to search for non-invasive, non-toxic and potent drug candidates for CL. In this sense, we have implemented a shape-based virtual screening approach and identified a set of 32 hit compounds. *In vitro* phenotypic screenings were conducted using these hit compounds to check their potential leishmanicidal effect towards *Leishmania amazonensis* (*L. amazonensis*). Two (Cp1 and Cp2) out of the 32 compounds revealed promising antiparasitic activities, exhibiting considerable potency against intracellular amastigotes present in peritoneal macrophages (IC₅₀ values of 9.35 and 7.25 μ M, respectively). Also, a sterile cidal profile was reached at 20 μ M after 48 h of incubation, besides a reasonable selectivity (≈ 8), quite similarly to pentamidine, a diamidine still in use clinically for leishmaniasis. Cp1 with an oxazolo[4,5-b]pyridine scaffold and Cp2 with benzimidazole scaffold could be developed by lead optimization studies to enhance their leishmanicidal potency.

Introduction

Cutaneous leishmaniasis (CL) is a vector-borne tropical neglected disease caused by over 20 different species of kinetoplastid parasites of the genus *Leishmania*. This disfiguring and stigmatizing disease occurs through the injection of promastigote forms into the mammals by infected female sandflies, triggering ulcers and permanent scars on the skin and/or oral and nasal mucosa injuries, thus contributing to high social stigmatization and public health issue (Bilgic-Temel *et al.*, 2019; WHO, 2020). Although about 1.2 million new cases occur annually, CL does not have adequate treatment that are mostly based on old and highly toxic drugs besides the occurrence of high number of parasite species with drug-resistance profile (Alvar *et al.*, 2012; de Vries *et al.*, 2015; Bailey *et al.*, 2019; ; Van Bocxlaer *et al.*, 2019).

Computer-aided drug design is an efficient strategy to identify active compounds. Shape-based screening has been successfully employed for the development of anti-fungal and anti-bacterial agents (Swinney and Anthony, 2011). The purpose of the shape-based screening is to identify chemically diverse compounds that show similar biological activity as the query compound. This is based on the principle that diverse structures that share similar shape and electrostatic potential surface or topology will have highest probability to bind to the same pocket and consequently share a similar activity (Kumar and Zhang, 2018).

Due to the limited information on targeted proteins of *Leishmania amazonensis*, we have chosen ligand-based shape screening approach for the hit identification process. The main advantages of this approach are that it only needs a single active compound as the starting point, and that a target crystal structure is not a requirement. This approach aids in the identification of diverse scaffolds other than the query compound scaffold, hence patent issues associated with the chemical space can be avoided.

Ligand-based shape screening was carried out using an active compound GNF5343 (Fig. 1) that displayed activity against the kinetoplastid parasites *Trypanosoma cruzi*, *Trypanosoma brucei* and *Leishmania donovani* (Khare *et al.*, 2016). To our knowledge, GNF5343 activity against *L. amazonensis* has not yet been reported. It has been suggested that the kinetoplastid parasites (*Leishmania* species and *Trypanosoma* species) share comparative genomic features (EI-Sayed *et al.*, 2005). GNF5343 activity against the three parasites suggests that this compound could be acting through a common receptor target. Hence, we have hypothesized that compounds that show shape similarity with GNF5343 should inhibit the common target and display activity against the *L. amazonensis*. Based on this hypothesis, we presently used GNF5343 as a query compound.




Fig. 1. Shape-based virtual screening results. (A) Illustrating the good alignment of query compound GNF5343 (orange sticks) with compound **2** (atom type coloured sticks). (B) Displaying maximum volume overlap that indicates good shape complementarity between the query compound (represented with mesh with an area of 300 \AA^2) and the compound **2** (represented with van der Waals molecular surface area of 326.5 \AA^2). (C) Molecular structures and their associated activity data. 1a and 1b images are generated using Phase-Schrödinger drug design software.

Thus, the urgent need for safer and selective potent drugs associated with promising aspects of identified diverse hit compounds from our ligand-based shape-screening programme encouraged us to perform *in vitro* phenotypic screening on amastigotes of *L. amazonensis*, which is one of the main agents of CL in the Americas (Martins *et al.*, 2014; de Vries *et al.*, 2015).

Methods

Compounds

All 32 identified hit compounds (Figs 1 and 2) that were purchased from Asinex commercial vendor and the reference drug, pentamidine (Pt), were dissolved in 99.99% dimethyl sulphoxide (DMSO) (stock solutions at 20 mM) and fresh dilutions prepared extemporaneously, with the final concentration never exceeding 0.6% DMSO for *in vitro* experiments, which does not induce host cell toxicity (Santos *et al.*, 2018).

Parasite strain and mammalian host cell cultures

Leishmania amazonensis (strain LTB0016) was used throughout the study. Male BALB/c mice were infected (10^6 amastigotes $20 \mu L^{-1}$ culture medium, *via* subcutaneous) at their foot paws, using a BD ultrafineTM 6 mm syringe (15/64") \times 31 G, following previous reported protocol, with minor modifications (Van Bocklaer *et al.*, 2019). After 30 days post infection, the animal skin lesions were aseptically removed, and the parasites obtained by mechanic dissociation (pipetting). The purified amastigotes were then assayed directly with the studied compounds to check the activity upon free amastigote (FA) forms, or used to infect primary cultures of peritoneal macrophages (PMM) to investigate their potency against intracellular forms (IA) (Feitosa *et al.*, 2019). Swiss male mice (18–20 g) were inoculated with 3% thioglycolate

and after 4 days, PMM collected by rinsing the animals' peritoneum with RPMI 1640. Mammalian cells were seeded at $24 (3 \times 10^5 \text{ cells well}^{-1})$ and 96-well ($5 \times 10^4 \text{ cells well}^{-1}$) plates and used for *in vitro* infection and host cell cytotoxicity analysis, respectively. The cultures were sustained at $37^\circ C$ with 5% CO_2 atmosphere in RPMI 1-640 medium (pH 7.2–7.4) without phenol red (Gibco BRL) but supplemented with 1% L-glutamine, penicillin–streptomycin $10\,000 \text{ U mL}^{-1}$, 10% fetal bovine serum (FBS). Assays using FA were also maintained at $32^\circ C$ using the same RPMI culture medium but adding 5% FBS instead of 10%.

Cytotoxicity upon mammalian host cells and leishmanicidal analysis

For cytotoxicity analysis, PMM were incubated for 48 h with increasing concentrations of the tested compounds (up to $500 \mu M$). Cellular viability was evaluated by AlamarBlue tests (Invitrogen) following the manufacturer's instructions (Da Silva *et al.*, 2007; Romanha *et al.*, 2010). The leishmanicidal activity was explored in two steps: in the first set of assays, amastigotes (10^6 parasites per well in 0.2 mL) purified from animal lesions (FA) were exposed for 48 h using a fixed concentration ($10 \mu M$) and then, drug activity assessed by AlamarBlue tests (Mikus & Sterverding, 2000). Then, in a second set of phenotypic screenings, the activity of the compounds was further validated on IA. In these assays, PMM (3×10^5) were infected with amastigotes (9×10^5 amastigotes) using multiplicity of infection (MOI) 3:1 (Van Bocklaer *et al.*, 2019). After 48 h of compound incubation (0 – $20 \mu M$), infected PMM were rinsed with saline buffered with phosphate (PBS), fixed with Bouin's solution and stained with Giemsa for light microscopy analysis (Santos *et al.*, 2018). Then, the percentage of infected host cells and the number of parasites per infected cells were scored for determination of the corresponding infection index (II) that represents the




Fig. 2. Clusters of hit compounds identified by shape-based virtual screening strategy. Cp 2a and Cp2b: % inhibition at 10 μ M.

multiplication factor of both parameters. Only characteristic parasite nuclei and kinetoplasts were counted as surviving parasites since irregular structures could mean parasites undergoing

death. The results were expressed as % of reduction of the parasite burden and the IC_{50} and IC_{90} calculated (Santos *et al.*, 2018). All assays were run in at least twice in three independent repeats.

Compound database preparation

Using the LigPrep module of the Schrödinger drug design software, a database (Asinex gold) of commercially available compounds was prepared by performing two-dimensional (2D) to three-dimensional (3D) conversion, addition of hydrogens, generation of ionization states, tautomeric states, stereoisomers and ring conformations at the physiological pH 7.0 ± 2.0 . Further, energy minimization of all the compounds was carried out using the molecular mechanics OPLS3 force field (Harder *et al.*, 2016). Compound selection was carried out by applying the Lipinski filter (molecular weight (mol. wt.) ≤ 500 ; calculated log P (cLogP) ≤ 5 ; H-bond acceptors (HBA) ≤ 10 ; H-bond donors (HBD) ≤ 5), besides removing the compounds with nitro groups and reactive functional groups (QikProp, Schrödinger release, 2017). A database was computed with a final set of 60 000 compounds.

Shape-based screening approach

The shape screening was performed using the phase module (Schrödinger-Phase, 2017). We used single 3D structure of GNF5343 compound as the query structure (Fig. 1). Compounds were screened by using the pharmacophore volume scoring setting which treats each compound as a collection of pharmacophore features. These features are aromatic groups, HBA groups, HBD groups, hydrophobic groups, positive charge groups and negative charge groups. Pharmacophoric tolerance was represented by a sphere of radius 2 Å. During the screening, 100 conformers were generated for each compound and the best 10 conformers were retained for matching pharmacophore features similarity. Phase similarity score (phase sim score) was computed based on the maximum aligned features for these conformers.

Cluster analysis

Schrödinger Canvas module was used to perform the cluster analysis as described (Schrödinger-Canvas manual, 2017). All the 31 compounds (Fig. 2) were processed using the hierarchical clustering algorithm with tanimoto similarity as a distance matrix. 2D fingerprints and atom pairs were used as metrics to quantify the chemical diversity.

Results

A subset of 31 compounds was selected based on the structural diversity and phase similarity score. Phase similarity score was computed from the maximum overlapping pharmacophore features as described in the method section. Clustering analysis was carried out on the selected subset of 31 compounds using a hierarchical clustering algorithm. A total of 11 clusters were identified (Fig. 2), of which five were singletons with diverse chemical structures such as quinoxaline derivative (cluster 4), imidazo [2,1-b]thiazole derivative (cluster 6), benzoxazole derivative (cluster 9), 2-oxo-2H-chromene derivative (cluster 10) and 3-imidazo [1,2-a] pyridine derivative (cluster 11). As the query compound GNF5343 was not available for purchase, we have selected one of its close analogue Cp1 (Fig. 1) for the comparative studies along with the selected set of 31 hit compounds. Cp1 differs from GNF5343 in having a thiophenyl ring substitution instead of furyl ring. All 32 compounds were purchased from Asinex and assayed using different protocols *in vitro*. A fixed concentration ($10 \mu\text{M}$) was first assessed on FA and findings demonstrated that two (Cp1 and Cp2) out of the 32 compounds reduced ($\geq 50\%$) the number of live parasites. Analogues of Cp2 from

cluster 1 (Fig. 1: Cps 2a and 2b) displayed weak inhibition (Fig. 2). Compounds from other clusters did not show any activity. While Cp1 is a close analogue of query compound, Cp2 is structurally diverse from GNF5343 in having benzimidazole scaffold. These active compounds (Cp1 and Cp2) and the reference drug pentamidine (Pt) were further analysed against FA using increasing concentrations of the tested compounds and Pt. The findings showed moderate leishmanicidal effect, with IC_{50} values of 13.03 ± 2.69 and $14.09 \pm 2.25 \mu\text{M}$ for Cp1 and Cp2, respectively, being less potent than Pt ($0.71 \pm 0.05 \mu\text{M}$).

In the second round of assays, the compounds were further evaluated against IA present in the cytoplasm of PPM, which represent the gold models for *in vitro* screening of leishmanicidal agents (DNDi, 2018). Our data showed that both compounds were active upon IA, exhibiting IC_{50} values of 9.35 ± 1.87 and $7.25 \pm 1.46 \mu\text{M}$, respectively, while Pt yielded $1.94 \pm 0.50 \mu\text{M}$. Against the IA, Cp1 and Cp2 reached low IC_{90} values ($17.25 \pm 0.21 \mu\text{M}$ and $18.54 \pm 0.96 \mu\text{M}$), exhibiting a leishmanicidal profile since both drastically dropped the number of parasites per cell as well as the percentage of infected PPM (Fig. 3). Regarding the mammalian host cell toxicity, we found that after 48 h of exposure, Cp1 and Cp2 were about 3-fold less toxic as compared to Pt, giving IC_{50} of 62.75 ± 0.27 and 65.39 ± 0.61 , with selectivity indexes of 6 and 9, respectively, in similar range than the reference drug (SI = 8).

In silico assessment of drug likeness and drug metabolism and pharmacokinetics (DMPK) properties is the most effective way in reducing time, expenses and maximizes the success in drug discovery process (Lombardo *et al.*, 2017). Therefore, drug likeness and DMPK properties were predicted for both Cp1 and Cp2 using the QikProp module (QikProp, Schrödinger release 2017–2). Recommended compliance scores are given in Table 1. The predicted properties of Cp1 and Cp2 showed compliance with 'Lipinski rule of five'. According to 'Jorgensen rule of three' any compound that met the recommended criteria (Table 1) are more likely to be orally available. The predicted properties of both Cp1 and Cp2 displayed compliance with 'Jorgensen rule of three'. Hence, these compounds could show good permeability and solubility properties. Both these properties are crucial for good oral bioavailability. QPPMDCK values are the prediction of MDCK cell permeability (nm/s), which is a good mimic for blood–brain permeation. According to this, both compounds displayed good blood–brain permeation. The efficiency of a drug may be affected by the extent at which it binds to human plasma protein. If compounds show high binding affinity to serum albumin this could lead to poor efficacy. Hence it is very crucial to understand the binding characteristics of Cp1 and Cp2. The predicted human serum albumin binding values (Table 1) for both Cp1 and Cp2 are within the permissible range indicating a lower binding affinity to the serum albumin protein.

Discussion

Compound GNF5343, an oxazolo[4,5-b]pyridine derivative (Fig. 1) was reported to display activity against *L. donovani* with an EC_{50} of $7.3 \pm 0.6 \mu\text{M}$, *T. cruzi* with an EC_{50} of $75 \pm 0.8 \text{ nM}$ and *T. brucei* with an EC_{50} of $150 \pm 7.5 \text{ nM}$ (Khare *et al.*, 2016). This active compound was used as a query compound to perform the shape-based virtual screening of a set of 60 000 chemically diverse compounds from the Asinex database. Compounds were ranked based on the phase similarity score. Phase similarity scores range from 0 (minimum similarity) to 1 (maximum similarity). Compounds with a phase similarity score above 0.85 were not considered in the selection as compounds with high similarity scores could be the close analogues of the query compounds.




Fig. 3. Light microscopy images of Giemsa-stained uninfected and infected PMM exposed or not (untreated control) to 10 and 20 μM of Cp1 and Cp2, demonstrating parasite sterilization at 20 μM . Arrows: intracellular parasites.

Table 1. *In silico* assessment of drug likeness and predicted DMPK properties of Cp1 and Cp2

		Recommended compliance score (range for 95% of drugs)	Compound ID	
			Cp1	Cp2
Lipinski rule of five	Mol. wt.	≤ 500	355.80	365.794
	HBD	≤ 5	1	2
	HBA	≤ 10	4	2
	cLogP	≤ 5	3.36	4.59
Jorgensen rule of three	QPlogS	-6.5 to 0.5	-5.380	-6.289
	QPCaco	<25 poor, >500 great	1403	1721
	Primary metabolites	<7	3	0
% Human oral absorption	-	>80% is high, <25% is low	100	100
QPPMDCK	-	>500 great, <25 poor	2650	3285
QPlogKhsa	-	-1.5 to 1.5	0.243	0.616

Mol. wt: molecular weight; HBD: hydrogen bond donor; HBA: hydrogen bond acceptor; cLogP: calculated logarithm of partition coefficient; QPlogS: the logarithm of aqueous solubility; QPCaco: Caco-2 cell permeability in nm/s, model for the gut–blood barrier; QPPMDCK: Madin–Darby canine kidney (MDCK) cell permeability in nm/s, model for the blood–brain barrier; QPlogKhsa: the logarithm of predicted binding constant to human serum albumin.

Compounds that are chemically diverse but similar shape to query compound GNF5343 with a shape similarity score between 0.85 and 0.6 were chosen for further analysis. These compounds were visually inspected to assess their structural diversity and synthetic accessibility. Compounds that showed poor shape similarity (phase similarity score less than 0.6) to query compound GNF5343 were not considered in the selection. Cp1 and Cp2 are the two active compounds identified from the selected set of 32 compounds as described under the results. Analysis of the

predicted alignments of these two compounds indicate that the root-mean-square deviation (RMSD) value for the maximum common structure between GNF5343 and Cp1 is 0.147 Å (figure not shown) and the RMSD value for the Cp2 is 1.569 Å (Fig. 1a). Both GNF5343 and Cp2 displayed maximum volume overlap (Fig. 1b) indicating that these two compounds are having similar topology to form similar van der Waals surface interactions at the same region. It is interesting to note the varied distribution of HBD, HBA and hydrophobicity between the basic scaffolds

(oxazolo[4,5-b]pyridine vs benzimidazole) of GNF5343 and Cp2. Both Cp1 and Cp2 displayed activity against *L. amazonensis* (Fig. 1c) with an EC₅₀ of 9.35 ± 1.87 μM and EC₅₀ of 7.25 ± 1.46 μM, respectively.

This activity of both Cp1 and Cp2 supports our hypothesis. Herein, we report two novel compounds active against *L. amazonensis*.

Currently, our analysis was performed using primary cultures of PMM infected with *L. amazonensis* since professional phagocytes are the main source of host cells for those obligate intracellular parasites (Walker *et al.*, 2014). This *in vitro* standardized experimental model for CL is claimed to closely reproduce *in vivo* conditions (Stacey, 2006), therefore, contributing to novel drug candidate screenings for this neglected illness (Chatelain and Ioset, 2011; Caridha *et al.*, 2019). Another interesting point to be addressed is the use of protocols that enable the identification of antiparasitic drugs that induces rapid parasite lysis (Da Silva *et al.*, 2007). This is especial characteristic as most of the CL patients live in very poor areas with difficult access to public health assistance and then, frequently display advanced pathologies, demanding a fast killer drug (Ruoti *et al.*, 2013; Okwor and Uzonna, 2016). Aiming to fulfill this demand, we established a period of 48 h of drug exposure while testing the parasites and host mammalian cells, a shorter period of incubation as compared with others reported in the current literature for CL *in vitro* models (Van Bocxlaer *et al.*, 2019).

This study explored the leishmanicidal effect of Cp1 (an analogue of GNF5343) and Cp2 (a benzimidazole analogue) identified using shape-based virtual screening approach. Both Cp1 and Cp2 achieved quite relevant potency against amastigotes, especially those lodged inside macrophages, reaching IC₅₀ values below 10 μM, a considerable characteristic preconized for a hit compound with anti-leishmania effect (Katsuno *et al.*, 2015). Remarkably, clearance on *L. amazonensis* infection was found at 20 μM in the infected PMM, a relevant feature to mitigate the possible occurrence of parasite drug resistance and relapses after ceasing the drug administration (Cal *et al.*, 2016). The Cp1 and Cp2 were less toxic than the reference drug (pentamidine) still in use for Leishmaniasis but their selectivity indexes (<10) discouraged to move them for *in vivo* proof of concept. However, their chemical optimization for a wider therapeutic window and promotion of potency is largely desirable to continue further studies using these compounds. Currently, we are performing structural modifications of Cp2 aiming to improve its potency, selectivity and satisfactory pharmacological profile, favouring future phenotypic studies in order to move its derivatives forward to new *in vitro* screening and *in vivo* evaluation, aiming to contribute for drug discovery process of new therapeutic approaches for CL. These analogues will also be tested against other kinetoplast parasites to assess their activity.

Acknowledgments. The authors thank the Fortalecimento dos Programas de Gestão Estratégica de Pesquisa da Fiocruz Rede de Plataformas Fiocruz (VPPLR - 001 - Fio 14) and the Programa de Excelência Acadêmica (PROEX) from CAPES.

Financial support. This study was supported by grants from Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional Desenvolvimento científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação Oswaldo Cruz, PDTIS, PAEF/CNPq/Fiocruz. MNCS is a research fellow of CNPq and CNE.

Conflicts of interest. None.

Ethical standards. All procedures were carried out in accordance with the guidelines established by the FIOCRUZ Committee of Ethics for the Use of Animals (CEUA L038/2017).

References

- Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano, J, Jannin, J and den Boer, M., & WHO Leishmaniasis Control Team (2012) Leishmaniasis worldwide and global estimates of its incidence. *PLoS ONE* 7, e35671.
- Bailey F, Mondragon-Shem K, Haines LR, Olabi A, Alorfi A, Ruiz-Postigo JA, Alvar J, Hotez P, Adams ER, Vélez ID, Al-Salem W, Eaton J, Acosta-Serrano Á and Molyneux DH (2019) Cutaneous leishmaniasis and co-morbid major depressive disorder: a systematic review with burden estimates. Cutaneous leishmaniasis and co-morbid major depressive disorder: a systematic review with burden estimates. *PLoS Neglected Tropical Diseases* 13, e0007092.
- Bilgic-Temel A, Murrell, DF and Uzun S (2019) Cutaneous leishmaniasis: a neglected disfiguring disease for women. *International Journal of Women's Dermatology* 5, 158–165.
- Cal M, Ioset J-R, Fügen MA, Mäser P and Kaiser M (2016) Assessing anti-*T. cruzi* candidates in vitro for sterile cidal activity. *International Journal for Parasitology: Drugs and Drug Resistance* 6, 165–170.
- Canvas (2017) Schrödinger Release 2017–2: Maestro, Schrödinger, LLC, New York, NY.
- Caridha D, Vesely B, van Bocxlaer K, Arana B, Mowbray CE, Rafati S, Uliana S, Reguera R, Kreishman-Deitrick M, Sciotti R, Buffet P and Croft SL (2019) Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. *International Journal for Parasitology: Drugs and Drug Resistance* 11, 106–117.
- Chatelain E and Ioset JR (2011) Drug discovery and development for neglected diseases: the DNDi model. *Drug Design, Development and Therapy* 16, 175–81.
- Da Silva CF, Batista MM, Mota RA, de Souza EM, Stephens CE, Som P, Boykin DW and Soeiro Mde N (2007) Activity of “reversed” diamidines against *Trypanosoma cruzi* “in Vitro”. *Biochemical Pharmacology* 73, 1939–46.
- de Vries HJ, Reedijk SH and Schallig HD (2015) Cutaneous leishmaniasis: recent developments in diagnosis and management. *American Journal of Clinical Dermatology* 16, 99–109.
- DNDi Annual report (2018) Making medical history. Available at https://www.dndi.org/wp-content/uploads/2019/07/DNDi_2018_AnnualReport.pdf (Accessed 8 March 2020).
- El-Sayed N, Myler P, Blandin G, Berriman M, Crabtree J, Aggarwal G, Caler E, Renauld H, Worthey E, Hertz-Fowler C, Ghedi E, Peacock C, Bartholomeu D, Haas B, Tran A, Wortman J, Alsmark Ucm, Angiuoli S, Anupama A, Badger J, Bringaud F, Cadag E, Carlton J, Cerqueira G, Creasy T, Delcher A, Djikeng A, Embley T, Hauser C, Ivens A, Kummerfeld S, Pereira-Leal J, Nilsson D, Peterson J, Salzberg S, Shallom J, Silva J, Sundaram J, Westenberger S, White O, Metville S, Donelson J, Andersson B, Stuart K and Hall N (2005) Comparative genomics of trypanosomatid parasitic protozoa. *Science* 309, 404–409.
- Feitosa LM, da Silva ER, Hoelz LVB, Souza DL, Come JAASS, Cardoso-Santos C, Batista MM, Soeiro MNC, Boechat N and Pinheiro LCS (2019) New pyrazolopyrimidine derivatives as *Leishmania amazonensis* arginase inhibitors. *Bioorganic & Medical Chemistry* 27, 3061–3069.
- Harder E, Damm W, Maple J, Wu C, Reboul M, Xiang JY, Wang L, Luypan D, Dahlgren MK, Knight JL, Kaus JW, Cerutti DS, Krilov G, Jorgensen WL, Abel R and Friesner RA (2016) OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. *Journal of Chemical Theory and Computation* 12, 281–296.
- Katsuno K, Burrows JN, Duncan K, van Huijsduijnen RH and Kaneko T (2015) Hit and lead criteria in drug discovery for infectious diseases of the developing world. *Nature Reviews Drug Discovery* 14, 751–758.
- Khare S, Nagle AS, Biggart A, Lai YH, Liang F, Davis LC, Barnes SW, Mathison CJN, Myburgh E, Gao MY, Gillespie JR, Liu X, Tan JL, Stinson M, Rivera IC, Ballard J, Yeh V, Groessl T, Federe G, Koh HXY, Venable JD, Bursulaya B, Shapiro M, Mishra PK, Spraggon G, Brock A, Mottram JC, Buckner FS, Rao SPS, Wen BG, Walker JR, Tuntland T, Molteni V, Glynne RJ and Supek F (2016) Proteasome inhibition for treatment of Leishmaniasis, Chagas disease and sleeping sickness. *Nature* 537, 229–233.
- Kumar A and Zhang KYJ (2018) Advances in the development of shape similarity methods and their application in drug discovery. *Frontiers in Chemistry* 6, 315.
- Lombardo F, Desai PV, Arimoto R, Desino KE, Fischer H, Keefer CE, Petersson C, Winiwarter S and Broccatelli F (2017) In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the international

- consortium for innovation through quality in pharmaceutical development. *Journal of Medical Chemistry* **60**, 9097–9113.
- Martins AL, Barreto JA, Lauris JR and Martins AC** (2014) American tegumentary leishmaniasis: correlations among immunological, histopathological and clinical parameters. *Anais Brasileiros de Dermatologia* **89**, 52–58.
- Mikus J and Sterverding D** (2000) A simple colorimetric to screen drug cytotoxicity against Leishmania using the dye Alamar blue. *Parasitology international* **48**, 265–269.
- Okwor I and Uzonna J** (2016) Social and economic burden of human leishmaniasis. *American Journal of Tropical Medical Hygiene* **94**, 489–493.
- QikProp** (2017) Virtual screening workflow, Schrödinger Release 2017-2: Maestro, Schrödinger, LLC, New York, NY.
- Romanha AJ, Castro SL, Soeiro Mde N, Lannes-Vieira J, Ribeiro I, Talvani A, Bourdin B, Blum B, Olivieri B, Zani C, Spadafora C, Chiari E, Chatelain E, Chaves G, Calzada JE, Bustamante JM, Freitas-Junior LH, Romero LI, Bahia MT, Lotrowska M, Soares M, Andrade SG, Armstrong T, Degraive W and Andrade Zde A** (2010) *In vitro* and *in vivo* experimental models for drug screening and development for Chagas disease. *Memórias do Instituto Oswaldo Cruz* **105**, 233–238.
- Ruoti M, Oddone R, Lampert N, Orué E, Miles MA, Alexander N, Rehman AM, Njord R, Shu S, Brice S, Sinclair B and Krentel A** (2013) Mucocutaneous leishmaniasis: knowledge, attitudes, and practices among Paraguayan communities, patients, and health professionals. *Journal of Tropical Medicine* **2013**, 538629. <https://doi.org/10.1155/2013/538629>
- Santos CC, Lionel JR, Peres RB, Batista MM, da Silva PB, de Oliveira GM, da Silva CF, Batista D, Souza S, Andrade CH, Neves BJ, Braga RC, Patrick DA, Bakunova SM, Tidwell RR and Soeiro M** (2018) *In vitro*, *in silico*, and *in vivo* analyses of novel aromatic amidines against *Trypanosoma cruzi*. *Antimicrobial Agents and Chemotherapy*, **62**: e02205–17.
- Stacey G** (2006) Primary cell cultures and immortal cell lines. *Encyclopedia of Life Sciences*. doi:10.1038/npg.els.0003960.
- Swinney DC and Anthony J** (2011) How were new medicines discovered? *Nature Reviews Drug Discovery* **10**, 507–519.
- Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, Wijnant GJ, Yardley V, Brillard S, Mowbray CE, Ioset JR and Croft SL** (2019) Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. *International Journal for Parasitology: Drugs and Drug Resistance* **11**, 129–138. doi: 10.1016/j.ijpddr.2019.02.002
- Walker DM, Oghumu S, Gupta G, McGwire BS, Drew ME and Satoskar AR** (2014) Mechanisms of cellular invasion by intracellular parasites. *Cellular and Molecular Life Sciences* **71**, 1245–1263.
- World Health Organization** (2020) Leishmaniasis factsheet – 2015 (last update 2 March 2020) Brazil. Available at <https://www.who.int/en/news-room/fact-sheets/detail/leishmaniasis> (Accessed 8 March 2020).